Lascufloxacin

Lascufloxacin (trade name Lasvic) is an fluoroquinolone antibiotic drug for the treatment of bacterial infections. It has been approved since 2019 in Japan to treat community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections.

It has activity against various Gram-positive bacteria including Streptococcus pneumoniae and Streptococcus anginosus.